← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06694532

NCT06694532 EffIcacy Between Arthrocentesis With High Versus Low Molecular Weight Hyaluronic Acid in Treatment of TMJ Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06694532
Status Recruiting
Phase Phase 1, Phase 2
Sponsor Basel khaled mohamed
Condition Temporomandibular Joint Disorders
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2023-10-31
Primary Completion 2026-02-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type INTERVENTIONAL
Interventions
Hyaluronic acidSyringes

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 30 participants in total. It began in 2023-10-31 with a primary completion date of 2026-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will be carried out in Patients in two Groups aged between 17 to 70 years , of both sexes, who had painful symptoms, with or without presence of joint noise, and had unilateral or bilateral internal derangement of the TMJ proven by clinical examination, with no improvement after conservative treatment.

Eligibility Criteria

Inclusion Criteria: * Pain or tenderness of the jaw * Pain in one or both of the temporomandibular joints * Aching pain in and around your ear * Difficulty chewing or pain while chewing * Aching facial pain * Locking of the joint, Exclusion Criteria: * Muscular TMJ disorders * Bleeding tendency

Contact & Investigator

Central Contact

Basel K Mohamed

✉ Basel_shrider@yahoo.com

📞 +201099848089

Principal Investigator

Basel K Mohamed

PRINCIPAL INVESTIGATOR

Assiut Univeristy

Frequently Asked Questions

Who can join the NCT06694532 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Temporomandibular Joint Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06694532 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT06694532 currently recruiting?

Yes, NCT06694532 is actively recruiting participants. Contact the research team at Basel_shrider@yahoo.com for enrollment information.

Where is the NCT06694532 trial being conducted?

This trial is being conducted at Asyut, Egypt.

Who is sponsoring the NCT06694532 clinical trial?

NCT06694532 is sponsored by Basel khaled mohamed. The principal investigator is Basel K Mohamed at Assiut Univeristy. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology